News & Events Year None201820172016201520142013201220112009 11/26/18 REGENXBIO and Rocket Pharmaceuticals Announce New License Agreement for the Treatment of Danon Disease Using NAV AAV9 Vector 11/14/18 FDA Grants Orphan Drug Designation To RGX-181 Gene Therapy For The Treatment Of CLN2 Form Of Batten Disease 11/07/18 REGENXBIO Reports Third Quarter 2018 Financial and Operating Results and Announces Initiation of Phase I/II Clinical Trial for RGX-121 for the Treatment of MPS II 11/06/18 REGENXBIO to Present at Upcoming Investor Conferences 11/05/18 REGENXBIO and Abeona Therapeutics Announce Worldwide Exclusive Licenses for the Treatment of Four Rare Lysosomal Storage Disorders Using NAV AAV9 Vector 10/31/18 REGENXBIO to Host Conference Call on November 7 to Discuss Third Quarter 2018 Financial Results and Recent Operational Highlights 10/26/18 REGENXBIO Announces Additional Positive Interim Phase I Trial Update for RGX-314 for the Treatment of Wet AMD at the American Academy of Ophthalmology 2018 Annual Meeting Pagination Current page 1 Page 2 Page 3 Page 4 Page 5 Next page next › Last page last »
